HCV Treatment
EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 14 April 2016 00:00
- Written by Liz Highleyman
A triple combination of Gilead Sciences' sofosbuvir, velpatasvir, and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior direct-acting antivirals (DAAs), according to 2 presentations at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.
EASL 2016: International Liver Congress Underway this Week in Barcelona
- Details
- Category: HCV Treatment
- Published on Wednesday, 13 April 2016 00:00
- Written by HIVandHepatitis.com
The European Association for the Study of the Liver's International Liver Congress (EASL 2016) takes place April 13-17 at Fira de Barcelona. The Congress is one of the key annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at Aidsmap will be providing on-site coverage starting Thursday, April 14.
CROI 2016: Advances in Hepatitis C Research [VIDEO]
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 April 2016 00:00
- Written by HIVandHepatitis.com
Interferon-free therapy can now cure most patients with chronic hepatitis C, but challenges still remain, including persistent liver damage and cancer risk and HCV reinfection after successful treatment. A panel of hepatitis C experts discuss research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) and related news with HIVandHepatitis.com editor Liz Highleyman in this IFARA video update.
CROI 2016: Hepatitis C [VIDEO]
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 April 2016 00:00
- Written by HIVandHepatitis.com
New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.
CROI 2016: Primary Care Providers Can Successfully Treat People with Hepatitis C
- Details
- Category: HCV Treatment
- Published on Thursday, 31 March 2016 00:00
- Written by Liz Highleyman
Direct-acting antiviral therapy for hepatitis C delivered by non-specialists such as primary care physicians and nurse practitioners is safe and effective -- even for the most difficult-to-treat patients -- and could potentially help increase the number of people receiving treatment, according to findings from the ASCEND study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last month in Boston.
More Articles...
- CROI 2016: Ravidasvir Plus Sofosbuvir Demonstrates High Cure Rate for HCV Genotype 4
- Coverage of the 2016 Conference on Retroviruses and Opportunistic Infections
- Daclatasvir Plus Asunaprevir Cures Most Genotype 1b Chinese Hepatitis C Patients
- FDA Approves Harvoni for Hepatitis C Patients with Advanced Liver Disease
Web Design and Development by